Our Commitment to Immunology
Immune diseases and disorders are some of the most common, affecting up to 24 million people in the United States. ONO is working toward drug discovery in two distinct but related areas of immunology: cancer immunotherapy and autoimmune therapy.
Our Approach to Immunology Research
The immune system plays roles in numerous diseases. We’re using novel strategies to understand and potentially modify the immune mechanisms that go awry – with the goal of turning those insights into therapies.
We are currently investigating a PD-1 x CD3 bispecific antibody, which has a novel mechanism of action, in T-cell lymphoma (U.S. and Japan), and across a range of autoimmune diseases (EU and Japan).
To go further in addressing unmet medical needs in autoimmune and inflammatory diseases, ONO collaborates with academic institutions and biotechs, which allows for more efficient discovery of potential immune therapies like antibodies and other promising medicines.
Immunology Pipeline Highlights
PD-1 x CD3 bispecific antibody
Our investigational PD-1 x CD3 bispecific antibody binds specifically to human PD-1 and CD3. Outside the U.S., it is being developed as a potential treatment for autoimmune diseases.
Bruton’s tyrosine kinase (BTK) inhibitor
Outside the U.S., an inhibitor of BTK, involved in B cell receptor signaling, is being investigated as a potential therapy for the autoimmune disease pemphigus.